Related references
Note: Only part of the references are listed.Assessment of specific immunotherapy efficacy using a novel placebo score-based method
Anthony J. Frew et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2012)
Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen
Lawrence H. DuBuske et al.
ALLERGY AND ASTHMA PROCEEDINGS (2011)
Sublingual Allergen-Specific Immunotherapy Adjuvanted with Monophosphoryl Lipid A: A Phase I/IIa Study
Oliver Pfaar et al.
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY (2011)
Innate immunity and adjuvants
Shizuo Akira
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2011)
Tolerance induction after specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A in children
M. Rosewich et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)
Ultra-short course immunotherapy in children and adolescents during a 3-yrs post-marketing surveillance study
Martin Rosewich et al.
PEDIATRIC ALLERGY AND IMMUNOLOGY (2010)
Pollinex Quattro Tree: allergy vaccine
Sandra M. Gawchik et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2009)
Allergen-related approaches to immunotherapy
Jennifer M. Rolland et al.
PHARMACOLOGY & THERAPEUTICS (2009)
Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)
J. Bousquet et al.
ALLERGY (2008)
Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines
Thomas Verstraeten et al.
VACCINE (2008)
Extract Modifications and Adjuvants for specific Immunotherapy
Randolf Brehler et al.
ALLERGO JOURNAL (2008)
GlaxoSmithKline Adjuvant systems in vaccines: concepts, achievements and perspectives
Nathalie Garcon et al.
EXPERT REVIEW OF VACCINES (2007)
The connection between allergic rhinitis and bronchial asthma
Jonathan Corren
CURRENT OPINION IN PULMONARY MEDICINE (2007)
Pollinex® Quattro:: a novel and well-tolerated, ultra short-course allergy vaccine
Piyush Patel et al.
EXPERT REVIEW OF VACCINES (2006)
Ultra-short-course seasonal allergy vaccine (Pollinex (R) Quattro)
Paul L. McCormack et al.
DRUGS (2006)
Monophosphoryl lipid A (MPL®) promotes allergen-induced immune deviation in favour of Th1 responses
F Puggioni et al.
ALLERGY (2005)
Allergy vaccines - new approaches to an old concept
AW Wheeler et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2004)
Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents
JR Baldridge et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2004)
Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies
N Mothes et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2003)
Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A
M Martin et al.
INFECTION AND IMMUNITY (2003)
Review of L-tyrosine confirming its safe human use as an adjuvant
P Baldrick et al.
JOURNAL OF APPLIED TOXICOLOGY (2002)
Safety evaluation of a glutaraldehyde modified tyrosine adsorbed housedust mite extract containing monophosphoryl lipid A (MPL®) adjuvant:: a new allergy vaccine for dust mite allergy
P Baldrick et al.
VACCINE (2001)
A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections
KJ Drachenberg et al.
ALLERGY (2001)
Consensus statement on the treatment of allergic rhinitis
P van Cauwenberge et al.
ALLERGY (2000)